高级检索
李东晓, 卢世栋, 胡晓, 宋云, 毋碧聪, 李亚飞, 李懿, 马红霞, 王海峰, 叶莹, 黄学勇. COVID-19确诊病例及灭活疫苗接种者不同时期血清IgA、IgM、IgG抗体检测结果比较[J]. 中国公共卫生, 2023, 39(9): 1159-1164. DOI: 10.11847/zgggws1139954
引用本文: 李东晓, 卢世栋, 胡晓, 宋云, 毋碧聪, 李亚飞, 李懿, 马红霞, 王海峰, 叶莹, 黄学勇. COVID-19确诊病例及灭活疫苗接种者不同时期血清IgA、IgM、IgG抗体检测结果比较[J]. 中国公共卫生, 2023, 39(9): 1159-1164. DOI: 10.11847/zgggws1139954
LI Dongxiao, LU Shidong, HU Xiao, SONG Yun, WU Bicong, LI Yafei, LI Yi, MA Hongxia, WANG Haifeng, YE Ying, HUANG Xueyong. Serum anti-SARS-CoV-2 IgA, IgM and IgG among confirmed COVID-19 cases at different stages and inactivated COVID-19 vaccine recipients after inoculation: a comparative analysis[J]. Chinese Journal of Public Health, 2023, 39(9): 1159-1164. DOI: 10.11847/zgggws1139954
Citation: LI Dongxiao, LU Shidong, HU Xiao, SONG Yun, WU Bicong, LI Yafei, LI Yi, MA Hongxia, WANG Haifeng, YE Ying, HUANG Xueyong. Serum anti-SARS-CoV-2 IgA, IgM and IgG among confirmed COVID-19 cases at different stages and inactivated COVID-19 vaccine recipients after inoculation: a comparative analysis[J]. Chinese Journal of Public Health, 2023, 39(9): 1159-1164. DOI: 10.11847/zgggws1139954

COVID-19确诊病例及灭活疫苗接种者不同时期血清IgA、IgM、IgG抗体检测结果比较

Serum anti-SARS-CoV-2 IgA, IgM and IgG among confirmed COVID-19 cases at different stages and inactivated COVID-19 vaccine recipients after inoculation: a comparative analysis

  • 摘要:
      目的   研究不同时期新型冠状病毒感染(COVID-19)病例及接种2019-nCoV灭活疫苗人群的抗体免疫应答规律及特点。
      方法   于2020年1月—2021年10月采集河南省43例COVID-19确诊病例的86份血清标本,46名灭活疫苗接种者的184份血清标本,50名未感染健康人的50份血清标本,采用磁微粒化学发光法和酶联免疫吸附法对320份血清标本检测并分析其抗体水平。
      结果   确诊病例恢复期IgA、IgM、IgG抗体阳性率高于急性期(P值均 < 0.05);恢复期的IgM、IgG抗体水平高于急性期(P值均 < 0.05)。灭活疫苗接种后31周,IgG和IgA抗体阳性率分别维持在63.04%(29/46)和36.96%(17/46),IgM抗体全部转阴;疫苗接种者第4、8、12、31周IgA抗体吸光度值差异无统计学意义(F = 2.365,P = 0.073),IgM、IgG抗体水平差异均有统计学意义(P < 0.05)。同时期确诊病例的IgA、IgM抗体阳性率高于疫苗接种者,IgM、IgG抗体水平高于疫苗接种者(P值均 < 0.05)。
      结论   IgG抗体在新型冠状病毒感染早期和恢复期阳性率最高。IgA、IgG抗体出现时间较IgM早,在疫苗接种者体内持续时间超过31周。同时期确诊病例的IgM、IgG抗体水平高于疫苗接种者。

     

    Abstract:
      Objective  To examine time-dependent variations in serum antibodies of severe acute respiratory disease coronavirus 2 (SARS-CoV-2) among confirmed coronavirus disease 2019 (COVID-19) cases at different stages and inactivated COVID-19 vaccine recipients after inoculation.
      Methods  The study was conducted in a city of Henan province. Totally 86 serum samples were collected from 43 confirmed COVID-19 cases at acute stage (1th – 23rd day of onset) and recovery state (25th – 58th day of onset) during January 2020 – October 2021; other 184 serum samples from 46 healthy recipients of inactivated COVID-19 vaccine at 4/8/12/31 weeks after inoculations and 50 serum samples from 50 residents without confirmed SARS-CoV-2 infections were also collected during March – October 2021. Anti-SARS-CoV-2 immunoglobulin A/G/M (IgA/G/M) were detected with magnetic particle chemiluminescence method and enzyme-linked immunosorbent assay for all the serum samples. The levels of the serum antibodies among the three groups′ participants were analyzed statistically.
      Results  Among the confirmed COVID-19 cases, the positivity rates of anti-SARS-CoV-2 IgA, IgM and IgG of the serum samples collected at recovery stage were significantly higher than those at acute stage (all P < 0.05) ; while, the concentrations of anti-SARS-CoV-2 IgM and IgG of the serum samples collected at recovery stage were significantly higher than those at acute stage (both P < 0.05). Among the healthy COVID-19 vaccine recipients 31 weeks after the inoculations, the positivity rate was 63.04% (29/46) for anti-SARS-CoV-2 IgG and 36.96% (17/46) for anti-SARS-CoV-2 IgA, but all samples were negative for anti-SARS-CoV-2 IgM. No significant differences were observed in the absorbance ratios anti-SARS-CoV-2 IgA among the samples collected 4, 8, 12, and 31weeks after the inoculation (F = 2.365, P = 0.073), but there were significant differences in the concentrations of anti-SARS-CoV-2 IgM and IgG (both P < 0.05) among the samples. Both the positivity rate of anti-SARS-CoV-2 IgA and IgM and the concentrations of anti-SARS-CoV-2 IgG and IgM were significantly higher among the confirmed COVID-19 cases than those among the inactivated COVID-19 vaccine recipients during a comparable period of time (P < 0.05 for all).
      Conclusion  The positivity rate of serum anti-SARS-CoV-2 IgG is the highest during early stage and recovery stage among COVID-19 cases. The positivity of serum anti-SARS-CoV-2 IgA and IgG occur earlier than that of IgM and could maintain till 31 weeks after the inoculation among inactivated COVID-19 vaccine recipients. The concentration of serum anti-SARS-CoV-2 IgG and IgM are higher among COVID-19 cases than those among inactivated COVID-19 vaccine recipients during a comparable period of time.

     

/

返回文章
返回